PHRX: AI 评分 55/100 — AI 分析 (4月 2026)

Pharmagen, Inc. distributes specialty drugs and pharmaceuticals to healthcare providers in the United States. The company also manufactures and distributes health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin.

Key Facts: AI Score: 55/100 Sector: Healthcare

公司概况

概要：

Pharmagen, Inc. is a US-based distributor of specialty drugs, blood plasma derivatives, and pharmaceuticals to hospitals and healthcare facilities. The company also manufactures and distributes health supplements, including Clotamin, catering to specific patient needs. Pharmagen operates within the competitive medical distribution sector, focusing on specialized and hard-to-find products.

PHRX是做什么的？

Pharmagen, Inc., formerly known as Sunpeaks Ventures, Inc., was established in January 2013 and is headquartered in Silver Spring, Maryland. The company operates as a distributor of specialty drugs and pharmaceuticals, serving hospitals, acute care facilities, surgery centers, and other healthcare practitioners across the United States. Pharmagen's core business involves sourcing and distributing a range of specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. These products cater to diverse medical needs, including treatments for cancer, hemophilia, rheumatoid arthritis, multiple sclerosis, blood disorders, hepatitis, and HIV. In addition to its distribution activities, Pharmagen manufactures and distributes health supplements, notably Clotamin, a specialized over-the-counter multivitamin dietary supplement formulated for patients on Warfarin. The company also offers traditional pharmaceuticals, such as antibiotics and vaccines, to its distribution customers, and specializes in drug formulation.

PHRX的投资论点是什么？

Pharmagen, Inc. operates in the niche market of specialty pharmaceutical distribution, focusing on hard-to-find drugs and plasma derivatives. With a small market capitalization of $0.00B and negative P/E ratio, the company presents a high-risk, high-reward investment profile. Key value drivers include the company's ability to maintain strong gross margins (63.3%) and its specialized product offerings like Clotamin. Growth catalysts include potential expansion into new geographic markets or therapeutic areas. However, investors should be aware of the risks associated with OTC-traded companies and Pharmagen's negative profit margin of -134.2%.

PHRX在哪个行业运营？

Pharmagen, Inc. operates within the medical distribution industry, which is characterized by increasing demand for specialty pharmaceuticals and biologics. The market is driven by an aging population, rising prevalence of chronic diseases, and advancements in medical treatments. The industry is highly competitive, with major players focusing on supply chain efficiency, product diversification, and strategic partnerships. Pharmagen differentiates itself by focusing on specialty drugs, hard-to-find pharmaceuticals, and manufacturing its own health supplements. The company's success depends on its ability to navigate complex regulatory requirements, maintain strong relationships with suppliers and customers, and adapt to evolving market trends.

Medical - Distribution

Healthcare

PHRX有哪些增长机遇？

Expansion of Clotamin Distribution: Pharmagen has the opportunity to expand the distribution of Clotamin, its specialized over-the-counter multivitamin for patients on Warfarin. The market for dietary supplements is projected to reach $86.1 billion by 2027, offering a significant growth avenue. Pharmagen can leverage its existing distribution network and marketing efforts to increase Clotamin sales and market share. Timeline: Ongoing.
Strategic Partnerships with Healthcare Providers: Pharmagen can pursue strategic partnerships with hospitals, acute care facilities, and surgery centers to become a preferred supplier of specialty drugs and pharmaceuticals. By offering customized solutions and value-added services, Pharmagen can strengthen its relationships with key customers and secure long-term contracts. The market for pharmaceutical distribution is estimated at $1 trillion globally. Timeline: Ongoing.
Geographic Expansion within the United States: Pharmagen can expand its geographic reach within the United States by targeting underserved markets and establishing new distribution centers. By increasing its presence in key regions, Pharmagen can enhance its ability to serve customers and capture a larger share of the market. The US pharmaceutical market is the largest in the world, valued at over $500 billion. Timeline: 2-3 years.
Development of New Specialty Drug Formulations: Pharmagen can leverage its expertise in drug formulation to develop new specialty drug products that address unmet medical needs. By investing in research and development, Pharmagen can create proprietary products that differentiate it from competitors and generate higher profit margins. The global market for specialty drugs is projected to reach $640 billion by 2027. Timeline: 3-5 years.
Acquisition of Complementary Businesses: Pharmagen can pursue acquisitions of complementary businesses, such as specialty pharmacies or pharmaceutical manufacturers, to expand its product portfolio and market reach. By acquiring companies with synergistic capabilities, Pharmagen can create economies of scale and enhance its competitive position. The M&A market in the pharmaceutical industry is highly active, with numerous opportunities for strategic acquisitions. Timeline: Ongoing.

Gross Margin of 63.3% indicates strong pricing power in its specialty drug distribution.
The company's Beta of 0.24 suggests lower volatility compared to the overall market.
Pharmagen's focus on specialty drugs and plasma derivatives caters to a niche market with specific medical needs.
The company's distribution network serves hospitals, acute care facilities, and surgery centers across the United States.
Pharmagen manufactures and distributes Clotamin, a specialized over-the-counter multivitamin dietary supplement for patients on Warfarin.

PHRX提供哪些产品和服务？

Distributes specialty drugs to hospitals and healthcare facilities.
Sources and distributes blood plasma derivatives.
Offers specialty products for treating respiratory, oncology, and cardiovascular conditions.
Provides vaccines and anti-infectives.
Manufactures and distributes health supplements, including Clotamin.
Specializes in the formulation of drugs.
Sells traditional pharmaceuticals, such as antibiotics and injectables.

PHRX如何赚钱？

Pharmagen generates revenue by distributing specialty drugs and pharmaceuticals to healthcare providers.
The company also earns revenue from the sale of its manufactured health supplements, such as Clotamin.
Pharmagen's business model focuses on sourcing hard-to-find pharmaceuticals and providing specialized services to its customers.

Hospitals
Acute care facilities
Surgery centers
Healthcare practitioners

Specialized product offerings, including hard-to-find pharmaceuticals.
Proprietary health supplement, Clotamin.
Established relationships with healthcare providers.
Expertise in drug formulation.

什么因素可能推动PHRX股价上涨？

Upcoming: Potential expansion of Clotamin distribution through new partnerships.
Ongoing: Strategic partnerships with healthcare providers to become a preferred supplier.
Ongoing: Efforts to develop new specialty drug formulations.
Ongoing: Potential acquisition of complementary businesses to expand product portfolio.

PHRX的主要风险是什么？

Potential: Intense competition in the pharmaceutical distribution industry.
Potential: Regulatory changes and compliance requirements.
Potential: Supply chain disruptions.
Potential: Economic downturn affecting healthcare spending.
Ongoing: Limited financial disclosure due to OTC listing.

PHRX的核心优势是什么？

Specialized product offerings (specialty drugs, plasma derivatives).
Proprietary health supplement (Clotamin).
Established distribution network.
High gross margin (63.3%).

PHRX的劣势是什么？

Small market capitalization.
Negative profit margin (-134.2%).
OTC-traded stock.
Limited financial resources.

PHRX有哪些机遇？

Expansion of Clotamin distribution.
Strategic partnerships with healthcare providers.
Geographic expansion within the United States.
Development of new specialty drug formulations.

PHRX面临哪些威胁？

Intense competition in the pharmaceutical distribution industry.
Regulatory changes and compliance requirements.
Supply chain disruptions.
Economic downturn affecting healthcare spending.

PHRX的竞争对手是谁？

Aqua Science, Inc. — Focuses on water purification and filtration systems. — (AQSZF)
Blue Flame Energy Corp. — Operates in the energy sector. — (BLFE)
Bronstein Energy Corp. — Engaged in oil and gas exploration. — (BNYN)
Emed Technologies Corp. — Develops and markets medical devices. — (EMED)
iVIX Funds Inc. — Offers investment funds and financial services. — (IVIXF)

Key Metrics

MoonshotScore: 55/100

Company Profile

CEO: Mackie A. Barch
Headquarters: Silver Spring, US
Employees: 24
Founded: 2012

AI Insight

AI analysis pending for PHRX

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Pharmagen, Inc. do?

Pharmagen, Inc. is a distributor of specialty drugs and pharmaceuticals to hospitals, acute care facilities, surgery centers, and other healthcare practitioners in the United States. The company sources and distributes a range of specialty drugs, blood plasma derivatives, specialty products, vaccines, anti-infectives, and hard-to-find pharmaceuticals. In addition to its distribution activities, Pharmagen manufactures and distributes health supplements, notably Clotamin, a specialized over-the-counter multivitamin dietary supplement formulated for patients on Warfarin. The company also offers traditional pharmaceuticals, such as antibiotics and vaccines, to its distribution customers, and specializes in drug formulation.

What do analysts say about PHRX stock?

As of March 16, 2026, there is no readily available analyst coverage for Pharmagen, Inc. (PHRX), likely due to its OTC listing and small market capitalization. Investors should conduct their own thorough due diligence and consider the risks associated with investing in OTC stocks. Key valuation metrics, such as P/E ratio, may not be meaningful due to the company's negative profitability. Growth considerations include the company's ability to expand its product offerings and distribution network.

What are the main risks for PHRX?

The main risks for Pharmagen, Inc. include intense competition in the pharmaceutical distribution industry, regulatory changes and compliance requirements, supply chain disruptions, and economic downturn affecting healthcare spending. Additionally, as an OTC-traded stock, PHRX faces risks related to limited financial disclosure, low trading volume and liquidity, higher price volatility, and potential for fraud or manipulation. Investors should carefully consider these risks before investing in PHRX.

What revenue streams does Pharmagen, Inc. have in healthcare?

Pharmagen, Inc.'s revenue streams primarily consist of sales from specialty drugs, blood plasma derivatives, and traditional pharmaceuticals to hospitals, acute care facilities, surgery centers, and healthcare practitioners. A secondary revenue stream is generated from the sale of their manufactured health supplements, including Clotamin, a specialized over-the-counter multivitamin dietary supplement. The specific breakdown of revenue by product line and therapeutic area is not publicly available.

How does Pharmagen, Inc. navigate regulatory approval processes?

As a distributor of pharmaceuticals, Pharmagen, Inc. must comply with regulations set forth by the FDA and other regulatory bodies. While the company does not directly manufacture prescription drugs requiring extensive clinical trials and approval processes, it must ensure that its sourcing, storage, and distribution practices adhere to strict quality control standards. Pharmagen also manufactures and distributes the health supplement Clotamin, which is subject to regulations governing dietary supplements. The company's specific track record and pending approvals are not publicly available.